Results of the Dutch scalp cooling registry in 7424 patients: analysis of determinants for scalp cooling efficacy

被引:1
作者
Brook, Toni S. [1 ]
Seetsen, Tanja [2 ]
Dercksen, Marcus W. [3 ]
van Riel, Annemarie [4 ]
Derleyn, Veerle A. [5 ]
van den Bosch, Johan [6 ]
Nortier, Johannes W. R. [7 ]
Collett, Andrew [1 ]
Georgopoulos, Nikolas T. [1 ,8 ]
Bryk, Jarek [1 ]
Breed, Wim P. M. [9 ]
van den Hurk, Corina J. G. [2 ]
机构
[1] Univ Huddersfeld, Sch Appl Sci, Dept Biol Sci, Huddersfeld, England
[2] Netherlands Comprehens Canc Org IKNL, Res & Dev Dept, Godebaldkwartier 419, NL-3511DT Utrecht, Netherlands
[3] Maxima Med Ctr, Oncol Dept, Eindhoven, Netherlands
[4] Elisabeth Twee Steden Hosp, Oncol Dept, Tilburg, Netherlands
[5] Elkerliek Hosp, Oncol Dept, Helmond, Netherlands
[6] Albert Schweitzer Hosp, Oncol Dept, Dordrecht, Netherlands
[7] Leiden Univ Med Ctr, Oncol Dept, Leiden, Netherlands
[8] Sheffeld Hallam Univ, Ind & Innovat Res Inst, Biomol Sci Res Ctr, Sheffeld, England
[9] Catharina Hosp, Oncol Dept, Eindhoven, Netherlands
关键词
CIA; Alopecia; chemotherapy; scalp cooling; hair loss; supportive care; CHEMOTHERAPY-INDUCED ALOPECIA; BREAST-CANCER; HAIR REGROWTH; PREVENTION; IMPACT; TIME;
D O I
10.1093/oncolo/oyae116
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Chemotherapy-induced alopecia is a common consequence of cancer treatment with a high psychological impact on patients and can be prevented by scalp cooling (SC). With this multi-center patient series, we examined the results for multiple currently used chemotherapy regimens to offer an audit into the real-world determinants of SC efficacy.Materials and methods The Dutch Scalp Cooling Registry collected data on 7424 scalp-cooled patients in 68 Dutch hospitals. Nurses and patients completed questionnaires on patient characteristics, chemotherapy, and SC protocol. Patient-reported primary outcomes at the start of the final SC session included head cover (HC) (eg, wig/scarf) use (yes/no) as a surrogate for patient satisfaction with SC and WHO score for alopecia (0 = no hair loss up to 3 = total alopecia) as a measure of scalp cooling success. Exhaustive logistic regression analysis stratified by chemotherapy regimen was implemented to examine characteristics and interactions associated with the SC result.Results Overall, over half of patients (n = 4191, 56%) did not wear a HC and 53% (n = 3784/7183) reported minimal hair loss (WHO score 0/1) at the start of their final treatment. Outcomes were drug and dose dependent. Besides the chemotherapy regimen, this study did not identify any patient characteristic or lifestyle factor as a generic determinant influencing SC success. For non-gender specific cancers, gender played no statistically significant role in HC use nor WHO score.Conclusions Scalp cooling is effective for the majority of patients. The robust model for evaluating the drug and dose-specific determinants of SC efficacy revealed no indications for changes in daily practice, suggesting factors currently being overlooked. As no correlation was identified between the determinants explaining HC use and WHO score outcomes, new methods for evaluation are warranted. Chemotherapy-induced alopecia is a common consequence of cancer treatment with a high psychological impact on patients and can be prevented by scalp cooling. This study examined the results of chemotherapy regimens to offer an audit into the real-world determinants of scalp cooling efficacy.
引用
收藏
页码:e1386 / e1395
页数:10
相关论文
共 51 条
  • [1] Use of in vitro human keratinocyte models to study the effect of cooling on chemotherapy drug-induced cytotoxicity
    Al-Tameemi, Wafaa
    Dunnill, Christopher
    Hussain, Omar
    Komen, Manon M.
    van den Hurk, Corina J.
    Collett, Andrew
    Georgopoulos, Nikolaos T.
    [J]. TOXICOLOGY IN VITRO, 2014, 28 (08) : 1366 - 1376
  • [2] Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia
    Bajpai, J.
    Kagwade, S.
    Chandrasekharan, A.
    Dandekar, S.
    Kanan, S.
    Kembhavi, Y.
    Ghosh, J.
    Banavali, S. D.
    Gupta, S.
    [J]. BREAST, 2020, 49 : 187 - 193
  • [3] Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment
    Betticher, Daniel C.
    Delmore, Geoffrey
    Breitenstein, Urs
    Anchisi, Sandro
    Zimmerli-Schwab, Beatrice
    Mueller, Andreas
    von Moos, Roger
    Huegli-Dayer, Anne Marguerite
    Schefer, Hubert
    Bodenmann, Sereina
    Buehler, Vera
    Trueb, Ralph R.
    [J]. SUPPORTIVE CARE IN CANCER, 2013, 21 (09) : 2565 - 2573
  • [4] Breed W. P., 2011, EXPERT REV DERMATOL, V6, P109, DOI DOI 10.1586/EDM.10.76
  • [5] Calcagno V, 2010, J STAT SOFTW, V34, P1
  • [6] Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients
    Choi, Eun Kyung
    Kim, Im-Ryung
    Chang, Oliver
    Kang, Danbee
    Nam, Seok-Jin
    Lee, Jeong Eon
    Lee, Se Kyung
    Im, Young-Hyuck
    Park, Yeon Hee
    Yang, Jung-Hyun
    Cho, Juhee
    [J]. PSYCHO-ONCOLOGY, 2014, 23 (10) : 1103 - 1110
  • [7] DigniCap, 2022, IS DIGNICAP AVAILABL
  • [8] Cooling-mediated protection from chemotherapy drug-induced cytotoxicity in human keratinocytes by inhibition of cellular drug uptake
    Dunnill, Christopher
    Ibraheem, Khalidah
    Peake, Michael
    Ioannou, Myria
    Palmer, Megan
    Smith, Adrian
    Collett, Andrew
    Georgopoulos, Nikolaos T.
    [J]. PLOS ONE, 2020, 15 (10):
  • [9] A Clinical and Biological Guide for Understanding Chemotherapy-Induced Alopecia and Its Prevention
    Dunnill, Christopher John
    Al-Tameemi, Wafaa
    Collett, Andrew
    Haslam, Iain Stuart
    Georgopoulos, Nikolaos Theodoros
    [J]. ONCOLOGIST, 2018, 23 (01) : 84 - 96
  • [10] Enzlin R., 2023, DEV PERSONALIZED SCA, V31, pS399